What to watch with ApoB and longevity?

ApoB (apolipoprotein B) is the primary protein component of LDL and VLDL particles and a more accurate marker of atherogenic risk than LDL cholesterol alone. For longevity, lower ApoB levels are consistently associated with reduced cardiovascular disease and extended healthspan. Each 10 mg/dL reduction in ApoB lowers cardiovascular events by ~20% in large trials. Key considerations: ApoB is modifiable through diet (saturated fat reduction, fiber), exercise, and medications (statins, PCSK9 inhibitors). Genetic variants in APOB, PCSK9, and LDLR can influence levels, but most variation is polygenic with small individual effects. DNA tests for ApoB-related genes have limited clinical utility for the general population; they are most useful for diagnosing familial hypercholesterolemia. For longevity, focus on achieving optimal ApoB levels (<50–70 mg/dL for high-risk individuals) rather than genetic testing. Evidence is strong (human-strong) from RCTs and Mendelian randomization studies. Safety note: any drug therapy should be guided by a physician.